Conventional Vs. Optimised Periprocedural Analgosedation Vs. Total Intravenous Anaesthesia for Pulsed-field Ablation: a Randomised Controlled Trial
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 127
- 试验地点
- 1
- 主要终点
- Primary composite endpoint (rate of hypoxaemia, hypotension, or hypertension events)
研究概览
简要总结
A prospective single blinded (subject blinded) 1:1:1 randomised control trial with three parallel arms testing superiority of analgosedation regimen based on remimazolam and total intravenous anesthesia over propofol based analgosedation. The primary composite endpoint consists of hypoxaemia, hypotension, or hypertension requiring intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Atrial fibrillation (AF) (paroxysmal, persistent or long standing persistent) with indication for catheter ablation
- •Age above 18 years
- •Capacity to give informed consent
排除标准
- •Heart failure (NYHA III-IV), irrespective of left ventricular ejection fraction
- •Left ventricular ejection fraction < 20%
- •Significant valvulopathy (moderate or severe aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, moderate and severe mitral stenosis, severe tricuspid regurgitation)
- •Obstructive sleep apnoea syndrome (AHI >30)
- •Low oxygen saturation (<93%) at baseline
- •High aspiration risk (hiatal hernia, gastroesophageal reflux disease on chronic pharmacotherapy)
- •Hypersensitivity to the study drugs
- •Chronic kidney disease (stage 4 and 5 of CKD), liver cirrhosis
- •Anticipated difficult airways
- •ASA (American Society of Anaesthesiologists) score > 4
- •Schizophrenia
- •Other individual contraindications (will be reported in detail)
研究组 & 干预措施
Arm P
Patients in arm P will be administered 2-3 mg midazolam IV before the beginning of the procedure, 5-10 mcg sufentanil IV and a loading dose of propofol 0,8-1,0 mg/kg in 2-5 minutes before the start of the ablation phase. During the procedure, boluses of 0,5 mg/kg propofol will be repeated as needed, in case of inappropriate analgosedation, boluses of midazolam and/or sufentanil can also 0be repeated.
干预措施: Propofol (Drug)
Arm R
Patients in arm R will be administered 2,5 mg loading dose of remimazolam followed by continuous infusion at 0,5 mg/h/kg of ideal body weight (IBW, calculated using the Miller formula) and a dose of ketamine 1 mg/kg IBW 2-5 minutes before the beginning of the ablation phase. In case of inadequate sedation depth, a bolus of 2,5 mg remimazolam can be repeated as needed. If the patient shows signs of pain or discomfort, a single dose of ketamine - 0,5 mg/kg IBW - will be administered, followed by a bolus of 5-10 mcg sufentanil if needed. The continuous infusion will be terminated as the last ablation pulses are delivered.
干预措施: Remimazolam (Drug)
Arm TIVA (Total Intravenous Anesthesia)
Patients randomised in arm TIVA will be administered light analgosedation with spontaneous ventilation for the first part of the procedure. The analgosedation will be induced and maintained with bolus of 5 mcg sufentanil IV and propofol infusion dosed by TCI system (the target plasma concentration for propofol 1-2 mcg/ml). Before the beginning of the ablation phase, general anesthesia will be induced with one bolus of 5-10 mcg sufentanil (the TCI target 3-7 mcg/ml for induction and 3-5 mcg/ml for the rest of the procedure), and a bolus of rocuronium 0,2-0,4 mg/kg IBW. Then, the airways will be secured with a laryngeal mask (LMA), the patient ventilated (0,4 - 0,45 FiO2, the target EtCO2 30 - 45 mmHg). After the last ablation pulse is delivered, infusion of propofol will be ceased and LMA extracted at the return of consciousness, muscle strength and sufficient spontaneous ventilation. If residual muscle relaxation occurs, sugammadex will be administered.
干预措施: Propofol (Drug)
结局指标
主要结局
Primary composite endpoint (rate of hypoxaemia, hypotension, or hypertension events)
时间窗: Procedure duration
Composite endpoint consisting of the rate of (1) hypoxaemia events requiring intervention, (2) hypotension events requiring intervention or leading to the procedure interruption, or (3) hypertension events requiring intervention
次要结局
- Total procedural time(Procedure duration)
- Total number of haemodynamic instability events (hypoxemia, hypotension, hypertension; defined above), each five minutes of a continuous instability counts as a new event, as well as an instability persisting despite an intervention(Procedure duration)
- Total number of: a) hypoxemia events hypoxaemia <85% (more than 60s) b) hypotension events = systolic blood pressure (SBP) < 85 mmHg (more than 60s) c) hypertension event = SBP > 200 mmHg (more than 60s)(Procedure duration)
- Total number of interventions a) jaw thrust b) nasopharyngeal airway administration c) LMA / orotracheal intubation d) increasing FiO2 (oxygen flow) e) hypotensive drugs administration f) vasoactive drugs administration (ephedrine, noradrenaline)(Procedure duration)
- Analgosedation depth by bispectral (BIS) monitoring: area under the curve of BIS index (measured every 3 minutes during the procedure)(Procedure duration)
- Procedural sedation quality(12-24 hours after the procedure)
- Difficult sedation score(Procedure duration)
- Operator's satisfaction score(Procedure duration)
- Total number of serious adverse events(From randomization until discharge)
- carbon dioxide partial pressure after the procedure(blood sample taken after the procedure (up to 10 minutes))
- 28-day serious adverese events(discharge to the day 28)
研究者
Marek Hozman, MD, PhD
Principal investigator
Charles University, Czech Republic